All In Biotech

NDA 021476 · Waylis Therap

Lunesta

Eszopiclone · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Aug 18, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Dec 15, 2004

Approved uses

2

Original approval plus efficacy supplements

Registered trials

71

17 Phase 3, 5 recruiting

FAERS reports

25,514

10,237 serious, 1,692 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: COMPLEX SLEEP BEHAVIORS Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of LUNESTA. Some of these events may result in serious injuries, including death. Discontinue LUNESTA immediately if a patient experiences a complex sleep behavior [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )]. WARNING: COMPLEX SLEEP BEHAVIORS See full prescribing information for complete boxed warning . Complex sleep behaviors including sleep-walking, sleep-driving, and engaging in other activities while not fully awake may occur following use of LUNESTA. Some of these events may result in serious injuries, including death. Discontinue LUNESTA immediately if a patient experiences a complex sleep behavior ( 4 , 5.1 ).

What it is approved for

From the label in effect Jan 8, 2025.

LUNESTA ® (eszopiclone) is indicated for the treatment of insomnia. In controlled outpatient and sleep laboratory studies, LUNESTA administered at bedtime decreased sleep latency and improved sleep maintenance. The clinical trials performed in support of efficacy were up to 6 months in duration. The final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6-week study (adults only), at the end of both 2-week studies (elderly only) and at the end of the 6-month study (adults only). LUNESTA is indicated for the treatment of insomnia. LUNESTA has been shown to decrease sleep latency and improve sleep maintenance ( 1 )

Mechanism: The mechanism of action of eszopiclone as a hypnotic is unclear; however, its effect could be related to its interaction with GABA-receptor complexes at binding domains located close to or allosterically coupled to benzodiazepine receptors.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • LUNESTA · ESZOPICLONE 2MG · TABLET, ORAL · Prescription · TE AB
  • LUNESTA · ESZOPICLONE 3MG · TABLET, ORAL · Prescription · TE AB
  • LUNESTA · ESZOPICLONE 1MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Eszopiclone" as an intervention, any sponsor and status, largest first.

All 71 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,890
  • insomnia3,913
  • dysgeusia3,855
  • nausea1,428
  • fatigue1,239
  • middle insomnia1,217
  • headache1,193
  • dizziness899
  • somnolence895
  • anxiety868
  • initial insomnia857
  • pain835

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20052,348
20064,423
20072,929
2008481
2009527
2010726
2011547
2012718
2013654
2014659
20151,010
20161,374
20171,123
20181,232
20191,148
20201,041
2021782
2022823
2023737
2024827
2025821
2026584

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lunesta (Eszopiclone)

2024 spending

$5.9M

Beneficiaries

963

5,408 claims

Per beneficiary

$6,172

$28.34 per unit

View as table
YearSpending
2020$5,718,493
2021$5,534,030
2022$4,925,760
2023$5,915,290
2024$5,944,116

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 105 on PubMed

Sponsor: Waylis Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.